BLUE - bluebird bio, Inc.
After hours:
| Previous close | 3.7100 |
| Open | 3.7100 |
| Bid | 3.7400 x 3100 |
| Ask | 3.7500 x 1300 |
| Day's range | 3.5900 - 3.7900 |
| 52-week range | 2.7800 - 8.5800 |
| Volume | |
| Avg. volume | 4,824,182 |
| Market cap | 396.917M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., May 09, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the first quarter ended March 31, 2023, including recent commercial and operational progress, and regulatory updates.
- Business Wire
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
SOMERVILLE, Mass., April 27, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company’s first quarter financial results, including commercial, regulatory and operational updates, will be released pre-market on Tuesday, May 9.
- Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
SOMERVILLE, Mass., April 24, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs). The BLA includes a request for Priority Review, which, if granted, would shorten the FDA’s review of the application to six months from the ti
- Business Wire
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., March 29, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates.
- Business Wire
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions
- Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
SOMERVILLE, Mass., January 18, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be c
- Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., January 09, 2023--bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT.
- Business Wire
bluebird bio Sells Second Priority Review Voucher for $95 Million
SOMERVILLE, Mass., January 06, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.
- Business Wire
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., January 05, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT.
- Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
SOMERVILLE, Mass., January 03, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial transactions, FDA regulations, compliance, manufacturing, and quality operations for organizations at all stages of development.
- Business Wire
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
SOMERVILLE, Mass., December 19, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD).
- Business Wire
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
SOMERVILLE, Mass., December 10, 2022--Today new and updated data from bluebird bio inc.’s (NASDAQ: BLUE) gene therapy programs in beta-thalassemia and sickle cell disease were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The updated data demonstrate sustained treatment effect in patients treated with betibeglogene autotemcel (beti-cel) and lovotibeglogene autotemcel (lovo-cel) gene therapies through additional follow-up. Case studies of two patients d
- Business Wire
bluebird bio Sells Priority Review Voucher for $102 Million
SOMERVILLE, Mass., November 30, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
- Business Wire
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., November 07, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress.
- Business Wire
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
SOMERVILLE, Mass., November 02, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 31st Annual Credit Suisse Healthcare Conference, Tuesday, November 8, at 5:00 p.m. PT at the Terranea Resort, Rancho Palos Verdes, CA.
- GlobeNewswire
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLOFLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to provide multiple health plans with access to an innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene autotem
- Business Wire
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
SOMERVILLE, Mass., September 17, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). The Company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted.
- Business Wire
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
SOMERVILLE, Mass., September 12, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that Jason Cole, Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunities.
- Business Wire
bluebird bio Announces September Investor Events
SOMERVILLE, Mass., August 29, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:
- Business Wire
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
SOMERVILLE, Mass., August 17, 2022--Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, including an innovative, outcomes-based contract offering and a comprehensive patient support program.
- Business Wire
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
SOMERVILLE, Mass., August 17, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
- Business Wire
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass, August 04, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.
- Business Wire
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
SOMERVILLE, Mass., June 10, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (RBC) transfusions.
- Business Wire
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
SOMERVILLE, Mass., June 09, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age who do not have an available and willing human leukocyte antigen (HLA)-matched sibling hematopoietic stem cell (HSC) donor.
- Business Wire
bluebird bio stock trading halted today June 9th and tomorrow June 10th
SOMERVILLE, Mass., June 09, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that Nasdaq has halted trading of the company’s common stock on Thursday, June 9 and Friday, June 10, 2022. The U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is meeting to discuss the biologics licensing applications (BLAs) for betibeglogene autotemcel (beti-cel) and elivaldogene autotemcel (eli-cel).
